Field Trial Validation of the Efficacy and Acceptability of Firocoxib, a Highly Selective Cox-2 Inhibitor, in a Group of 96 Lame Horses

Journal of Equine Veterinary Science

Volumn 30, Issue 5, 2010, Pages 237-243

  Koene, Marc ^a   Goupil, Xavier ^b   Kampmann, Clemens ^c   Hanson, Peter D ^d   Denton, Davida ^d   Pollmeier, Matthias G ^d  

^a Tierklinik Lüsche ^*  (Germany)

^b Ecole Nationale d'Equitation   (France)

^c Tierklinik Wahlstedt   (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EQUIDAE;

EID: 77953313054     PISSN: 07370806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jevs.2010.03.011     Document Type: Article

References (28)

1. Stashak T.S. Examination of lameness. In: Stashak T.S. (Ed). Adams' lameness in horses. 5th ed (2002), Lippincott Williams & Wilkins, Philadelphia, PA 113-183
2. Casey J. Healthy Horses Workshop, held in conjunction with the American Association of Equine Practitioners 52nd annual convention; December 2, 2006; San Antonio, TX.
3. Jeffcott L.B., Rossdale P.D., and Freestone J.E. An assessment of wastage in thoroughbred racing from conception to 4 years of age. Equine Vet J 14 (1982) 185-198
4. Morris E.A., and Seeherman H.J. Clinical evaluation of poor performance in the racehorse: the results of 275 evaluations. Equine Vet J 23 (1991) 169-174
5. Fitzpatrick F.A. Cyclooxygenase enzymes: regulation and function. Curr Pharm Des 10 (2004) 577-588
6. Wilson J.E., Chandrasekharan N.V., Westover K.D., Eager K.B., and Simmons D.L. Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res 65 (2004) 810-818
7. Vane JR, Botting RM. The history of anti-inflammatory drugs and their mechanism of action. In: Bazan NG, Botting J, Vane JR, eds. Proceedings of the New targets in inflammation. Inhibitors of Cox-2 on adhesion molecules; April 15-16, 1996; New Orleans, LA.
8. Wallace J.L., Reuter B.K., Mcknight W., and Bak A. Selective inhibitors of cyclooxygenase-2: are they really effective, selective, and GI-safe?. J Clin Gastroenterol 27 Suppl 1 (1998) S28-S34
9. Zimmermann K.C., Sabria M., Schrör K., and Weber A.-A. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol 54 (1998) 536-540
10. Wolfe M.M., Lichtenstein D.R., and Gurkirpal S. Gastrointestinal toxicity of nonsteroidal antiinflammtory drugs. N Engl J Med 340 (1999) 1888-1899
11. Gilroy D.W., and Colville-Nash P.R. New insights into the role of COX-2 in inflammation. J Mol Med 78 (2000) 121-129
12. Macnaugthon W.K., and Cushing K. Role of constitutive Cox-2 in prostaglandin-dependent secretion in Mouse Colon in vitro. J Pharmacol Exp Ther 293 (2000) 539-544
13. Brzozowski T., Konturek P.C., Konturek S.J., Sliwowski Z., Pajdo R., Drozdowicz D., et al. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. Microsc Res Tech 53 (2001) 343-353
14. Khan K.N.M., Stanfield K.M., Trajkovic D., and Harris R.K. Expression of cyclooxygenase-2 in canine renal cell carcinoma. Vet Pathol 38 (2001) 116-119
15. Einhorn T.A. The role of cyclooxygenase-2 in bone repair. Arthritis Res Ther 5 (2002) 5-7
16. Warner T.D., and Mitchell J.A. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 18 (2004) 790-804
17. Brzozowska I., Targosz A., Sliwowski Z., Kwiecien S., Drozdowicz D., Pajdo R., et al. Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (NO)-derivative of aspirin and cyclooxygenase (COX)-2 inhibitor. J Physiol Pharmacol 55 (2004) 773-790
18. McCann M.E., Andersen D.R., Brideau C., Black W.C., Zhang D.-H., and Hickey G.J. In vitro activity and in vivo efficacy of a novel Cox-2 inhibitor in the horse (abstract). J Vet Int Med 16 (2002) 355
19. Bergh M.S., and Budsberg S.C. The coxib NSAIDs: potential clinical and pharmacologic importance in veterinary medicine. J Vet Intern Med 19 (2005) 633-643
20. Sackett D.L., Straus S.E., Richardson W.S., Rosenberg W., and Haynes R.B. Evidence-based medicine: how to practice and teach EBM (2000), Churchill Livingston, London ISBN 0-443-06240-4
21. Viitanen M., Bird J., Maisi P., Smith R., Tulamo R.M., and May S. Differences in the concentration of various synovial fluid constituents between the distal interphalangeal joint, the metacarpophalangeal joint and the navicular bursa in normal horses. Res Vet Sci 69 (2000) 63-67
22. Malone E.D. Managing chronic arthritis. Vet Clin North Am Equine Pract 18 (2002) 411-437
23. Doucet M.Y., Bertone A.L., Hendrickson D., Hughes F., MacAllister C., McClure S., et al. Comparison of efficacy and safety of paste formulations of firocoxib and phenylbutazone in horses with naturally occurring osteoarthritis. J Am Vet Med Assoc 232 (2008) 91-97
24. MacAllister C.G., Morgan S.J., Borne A.T., and Pollet R.A. Comparison of adverse effects of phenylbutazone, flunixin meglumine, and ketoprofen in horses. J Am Vet Med Assoc 202 (1993) 71-77
25. Monreal L., Sabate D., Segura D., Mayos I., and Homedes J. Lower gastric ulcerogenic effect of suxibuzone compared to phenylbutazone when administered orally to horses. Res Vet Sci 76 (2004) 45-149
26. Meschter C.L., Gilbert M., Krook L., Maylin G., and Corradino R. The effects of phenylbutazone on the intestinal mucosa of the horse: a morphological, ultrastructural and biochemical study. Equine Vet J 22 (1990) 255-263
27. Ramirez S., Seahorn T.L., and Williams J. Renal medullary rim sign in 2 adult quarter horses. Can Vet J 39 (1998) 647-649
28. Goodrich L.R., Furr M.O., Robertson J.L., and Warnick L.D. A toxicity study of eltenac, a nonsteroidal anti-inflammatory drug, in horses. J Vet Pharmacol Ther 21 (1998) 24-33